Hanall Biopharma Operating Profit Grows; Q3 Profit Expands Despite Lower Sales
Predicted impact: Low
Q3 operating profit of about ₩1.3B is small in absolute terms and was already reported in the window.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.